Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2406485rdf:typepubmed:Citationlld:pubmed
pubmed-article:2406485lifeskim:mentionsumls-concept:C1335749lld:lifeskim
pubmed-article:2406485lifeskim:mentionsumls-concept:C1709900lld:lifeskim
pubmed-article:2406485lifeskim:mentionsumls-concept:C0751571lld:lifeskim
pubmed-article:2406485lifeskim:mentionsumls-concept:C1261322lld:lifeskim
pubmed-article:2406485lifeskim:mentionsumls-concept:C0805443lld:lifeskim
pubmed-article:2406485lifeskim:mentionsumls-concept:C1578536lld:lifeskim
pubmed-article:2406485lifeskim:mentionsumls-concept:C0868928lld:lifeskim
pubmed-article:2406485pubmed:issue1lld:pubmed
pubmed-article:2406485pubmed:dateCreated1990-3-27lld:pubmed
pubmed-article:2406485pubmed:abstractTextRegistration of renal pelvic and ureteral tumor was done from 1980 through 1986, in the Tokai Urological Tumor Registry. Among the 404 cases of the carcinoma, 384 cases (210 renal pelvis, 174 ureter) were subjected to the present study. A total of 319 cases (83.1%) showed a complete cure, while 20 cases (5.2%) were considered as partial cure, and 45 cases (11.7%) were classified to progressive disease group. Chemotherapy was performed on 151 patients including systemic administration to 141 patients (33.9%) and 11 patients received combined intravesical instillation therapy. Irradiation was performed on 49 patients (12.8%). Degree of histological and morphological differentiation of renal pelvis and ureter tumor were studied in 341 cases of transitional cell carcinoma (88.8%); G0, 0.3%, G1, 12.9%, G2, 49.3%, Gx, 5.2%. Stage of the tumor were T1, 33.6%; T2, 12.5%; T3, 14.6%; T4, 13.3%; Tis, 0.3%; Tx, 24.7%. Five-year relative survival for carcinoma of the renal pelvis was 46.6%, and for the ureter it was 53.1%. Five-year survival according to histological differentiation of transitional cell carcinoma and according to the stage of the tumor were as follows; G1, 91.6%; G2, 58.5%; G3, 27.2%; Ta, 84.6%; T1. 74.2%; T2, 48.5%; T3, 24.1%, T4, 7.3%. The rate of survival was correlated with histological differentiation of the tumor cells. The survival was poor in cases who had the components of squamous cell carcinoma and/or adenocarcinoma. Overall survived case were 177, 122 patients died of cancer, 20 patients died of other causes than cancer, and 1 patient died from immediate surgical effect.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:2406485pubmed:languagejpnlld:pubmed
pubmed-article:2406485pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2406485pubmed:citationSubsetIMlld:pubmed
pubmed-article:2406485pubmed:statusMEDLINElld:pubmed
pubmed-article:2406485pubmed:monthJanlld:pubmed
pubmed-article:2406485pubmed:issn0021-5287lld:pubmed
pubmed-article:2406485pubmed:authorpubmed-author:OhshimaSSlld:pubmed
pubmed-article:2406485pubmed:authorpubmed-author:OtaniTTlld:pubmed
pubmed-article:2406485pubmed:authorpubmed-author:MoraGGlld:pubmed
pubmed-article:2406485pubmed:authorpubmed-author:UedaKKlld:pubmed
pubmed-article:2406485pubmed:authorpubmed-author:ObataKKlld:pubmed
pubmed-article:2406485pubmed:authorpubmed-author:KuriyamaMMlld:pubmed
pubmed-article:2406485pubmed:authorpubmed-author:NaruseKKlld:pubmed
pubmed-article:2406485pubmed:authorpubmed-author:IsogaiKKlld:pubmed
pubmed-article:2406485pubmed:authorpubmed-author:AsakaHHlld:pubmed
pubmed-article:2406485pubmed:authorpubmed-author:FujnimotoYYlld:pubmed
pubmed-article:2406485pubmed:issnTypePrintlld:pubmed
pubmed-article:2406485pubmed:volume81lld:pubmed
pubmed-article:2406485pubmed:ownerNLMlld:pubmed
pubmed-article:2406485pubmed:authorsCompleteYlld:pubmed
pubmed-article:2406485pubmed:pagination110-5lld:pubmed
pubmed-article:2406485pubmed:dateRevised2011-7-28lld:pubmed
pubmed-article:2406485pubmed:meshHeadingpubmed-meshheading:2406485-...lld:pubmed
pubmed-article:2406485pubmed:meshHeadingpubmed-meshheading:2406485-...lld:pubmed
pubmed-article:2406485pubmed:meshHeadingpubmed-meshheading:2406485-...lld:pubmed
pubmed-article:2406485pubmed:meshHeadingpubmed-meshheading:2406485-...lld:pubmed
pubmed-article:2406485pubmed:meshHeadingpubmed-meshheading:2406485-...lld:pubmed
pubmed-article:2406485pubmed:meshHeadingpubmed-meshheading:2406485-...lld:pubmed
pubmed-article:2406485pubmed:meshHeadingpubmed-meshheading:2406485-...lld:pubmed
pubmed-article:2406485pubmed:meshHeadingpubmed-meshheading:2406485-...lld:pubmed
pubmed-article:2406485pubmed:meshHeadingpubmed-meshheading:2406485-...lld:pubmed
pubmed-article:2406485pubmed:meshHeadingpubmed-meshheading:2406485-...lld:pubmed
pubmed-article:2406485pubmed:meshHeadingpubmed-meshheading:2406485-...lld:pubmed
pubmed-article:2406485pubmed:meshHeadingpubmed-meshheading:2406485-...lld:pubmed
pubmed-article:2406485pubmed:meshHeadingpubmed-meshheading:2406485-...lld:pubmed
pubmed-article:2406485pubmed:meshHeadingpubmed-meshheading:2406485-...lld:pubmed
pubmed-article:2406485pubmed:meshHeadingpubmed-meshheading:2406485-...lld:pubmed
pubmed-article:2406485pubmed:meshHeadingpubmed-meshheading:2406485-...lld:pubmed
pubmed-article:2406485pubmed:year1990lld:pubmed
pubmed-article:2406485pubmed:articleTitle[Carcinoma of the renal pelvis and ureter. An investigation of 384 registered cases in the Tokai Urological Cancer Registry].lld:pubmed
pubmed-article:2406485pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2406485pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2406485pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:2406485pubmed:publicationTypeMulticenter Studylld:pubmed